Arbutus Appoints Two New Executives
Retrieved on:
Monday, July 10, 2023
KRYS, Employment, University, Therapy, General counsel, Willamette University College of Law, HIV, Virology, Liz, Van Sweringen railroad holdings, Infection, Drug, Viral, Bristol Myers Squibb, Koch Industries, Doctor of Philosophy, Bates College, Assistant, BMY, Hospital of the University of Pennsylvania, Arbutus, Lung transplantation, Medical director, Patent, MD, Patient, Internal medicine, Oklahoma Office of the Chief Medical Examiner, Corporation, RNA interference, Hospital, Blank Rome, HCV, Hampden–Sydney College, HBV, NYSE, Behavioral neuroscience, Compensated emancipation, Pharmaceutical industry, Neuroscience, Medicine
WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Christopher Naftzger as General Counsel and Chief Compliance Officer. Mr. Naftzger succeeds Dr. Elizabeth Howard who will continue in an advisory role with respect to the on-going patent infringement litigations. Both Dr. Sims and Mr. Naftzger will report directly to William Collier, Arbutus President and Chief Executive Officer, effective immediately.
Key Points:
- Both Dr. Sims and Mr. Naftzger will report directly to William Collier, Arbutus President and Chief Executive Officer, effective immediately.
- “Karen has played an integral role in the clinical development of AB-729, our lead RNAi therapeutic, during her six-year tenure at Arbutus, and has continued to advance our pipeline of HBV programs.
- Prior to joining Arbutus, Dr. Sims held multiple positions during her seven-year tenure at Bristol-Myers Squibb (NYSE: BMY).
- Christopher Naftzger joins Arbutus with more than 25 years of legal experience, including over a decade of experience serving as senior in-house counsel with life science companies.